恒瑞医药：瑞维鲁胺片获前列腺癌Ⅲ期临床试验批准

Core Viewpoint - The announcement from Heng Rui Medicine indicates that the National Medical Products Administration has approved the clinical trial for Ruvelimab tablets, specifically for Phase III trials in prostate cancer [1] Group 1: Product Development - Ruvelimab tablets are classified as a second-generation AR inhibitor and were approved for market launch in 2022 [1] - The global sales for similar products are projected to reach approximately $11.037 billion in 2024 [1] - The cumulative R&D investment for this product has reached about 693.09 million yuan [1] Group 2: Regulatory Approval - The approval from the National Medical Products Administration allows for the commencement of clinical trials, which is a critical step in the drug development process [1] - The approval specifically pertains to the Phase III clinical trial for prostate cancer, indicating a significant advancement in the product's development timeline [1] Group 3: Industry Context - The drug development and market launch cycle is characterized by its lengthy and complex nature, which introduces various uncertainties [1]